SF-based Arterys, a Rosenman Innovator, is a medical imaging software developer for clinical AI products.
>>>>>>>>>>>>>>>>>>>>.
Arterys, a medical imaging software developer for clinical AI products, announced today that it raised $28 million in a Series C financing round.
Benslie Investment Group and Temasek Holdings led the funding, while Fosun, Revelation Partners, Emergent Medical Partners and Varian Medical Systems participated as well.
San Francisco-based Arterys said in a news release that it intends to use the funds to broaden its ecosystem, which includes a broad set of partners on its new marketplace that utilizes its cloud platform.
Much focus will gear toward accelerating partners’ efforts to bring new, clinical-grade AI applications to providers by extending the Arterys technology platform to application partners so they can integrate AI into their workflows, the company said.
Additionally, Arterys appointed co-founder John Axerio-Cilies as its acting CEO. According to a previous press release, Axerio-Cilies previously held the role of chief technology officer at the company as well.
“We realize that we can’t transform the healthcare system alone,” Axerio-Cilies said. “No company can. And now, the same technology and strengths that we’ve leveraged to build our core products [Arterys Cardio AI and Arterys Lung AI] are now available to medical innovators at companies and universities around the world — they can benefit from regulatory support, channel partnerships, performance, security, and best-in-class hospital system integrations.”
“The current crisis has shown us the necessity of a different approach to providing healthcare, where technology and AI are crucial for future success,” added Benslie International managing partner Henry Weinstein. “Arterys is committed to transforming the way AI is integrated into the medical workflow, a promise that is long due in the industry. We recently launched our cloud platform and marketplace that will consolidate the work of thousands of AI models to be readily available for use by healthcare institutions around the globe.”